Huons acquires U.S. patent of ‘nanodrop’

Huons(CEO Ki-Ahn Um) announced on the 25^th that the company acquired the U.S. approval of the ‘nanodrops(HU-007)’ being developed with a Korean Phase III clinical trial.

The U.S. patent is the manufacturing method and therapy of the dermatologic nanodrop containing cyclosporine and trehalose, and acquired a patent in Korea first in 2016. In addition to this, it is in the progress of assessment...